A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort

Personalized Medicine

Volumn 7, Issue 3, 2010, Pages 319-325

  Gladding, Patrick ^a,b,c   MacKay, John ^d,e   Zeng, Irene ^a   Stewart, Ralph ^a   Prabkahar, Rishi ^f   Webster, Mark ^a   White, Harvey ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b Theranostics Laboratory   (New Zealand)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Linnaeus Laboratory   (New Zealand)

^e Dnature   (New Zealand)

^f Palisade Corporation   (United States)

Author keywords

M ori; Pacific Islanders; Pharmacogenetic; Simulation; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; AGED; ARTICLE; BODY SURFACE; BOOTSTRAPPING; CHINESE; COHORT ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEALTH DISPARITY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETER; NEW ZEALAND; PACIFIC ISLANDER; PHARMACOGENETICS; PRIORITY JOURNAL; SIMULATION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

EID: 77951871155     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.24     Document Type: Article

References (31)

1. Gage BF, Eby C, Johnson JA et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84 (3), 326-331 (2008). (Pubitemid 38111225)
2. Describes the basis for the pharmacogenetic algorithm used in this paper.
3. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, Mcleod HL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91 (1), 87-94 (2004). (Pubitemid 38111225)
4. Describes the basis for the pharmacogenetic algorithm used in this paper.
5. D'andrea G, D'ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2), 645-649 (2005).
6. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired S-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4 (1), 39-42 (1994).
7. Caldwell MD, Awad T, Johnson JA et al.: CYP4F2 genetic variant alters required warfarin dose. Blood 111 (8), 4106-4112 (2008).
8. Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5 (4), 262-270 (2005). (Pubitemid 41131718)
9. Zhao F, Loke C, Rankin SC et al.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76 (3), 210-219 (2004). (Pubitemid 39221795)
10. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16 (2), 101-110 (2006). (Pubitemid 43145678)
11. Mushiroda T, Ohnishi Y, Saito S et al.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet. 51 (3), 249-253 (2006).
12. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14 (13), 1745-1751 (2005).
13. Geisen C, Watzka M, Sittinger K et al.: VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94 (4), 773-779 (2005). (Pubitemid 41489236)
14. Describes the VKORC1 haplotypes in detail.
15. Wu AH, Wang P, Smith A et al.: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9 (2), 169-178 (2008). (Pubitemid 351566941)
16. Lea RA, Roberts RL, Green MR, Kennedy MA, Chambers GK: Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Mãori. N. Z. Med. J. 121 (1272), 33-37 (2008).
17. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116 (22), 2563-2570 (2007).
18. First trial of genotype-guided warfarin therapy.
19. Eckman MH, Rosand J, Greenberg SM, Gage BF: Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 150 (2), 73-83 (2009).
20. Cost-effectiveness analysis showing cost-benefit for pharmacogenetic testing for warfarin and providing certain restrictions, for example cost must be less than US$200.
21. Sullivan-Klose TH, Ghanayem BI, Bell DA et al.: The role of the CYP2C9-leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 (4), 341-349 (1996).
22. Gage BF, Eby CS: Pharmacogenetics and anticoagulant therapy. J. Thromb. Thrombolysis 16 (1-2), 73-78 (2003).
23. Kimura R, Miyashita K, Kokubo Y et al.: Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res 120 (2), 181-186 (2007). (Pubitemid 46754413)
24. Takahashi H, Wilkinson GR, Caraco Y et al.: Population differences in S-warfarin metabolism between CYP2C9 genotypematched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73 (3), 253-263 (2003). (Pubitemid 36269676)
25. Loebstein R, Dvoskin I, Halkin H et al.: A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109 (6), 2477-2480 (2007). (Pubitemid 46425891)
26. Schwartz RS: Racial profiling in medical research. N. Engl. J. Med. 344 (18), 1392-1393 (2001).
27. Caraco Y, Blotnick S, Muszkat M: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83 (3), 460-470 (2008). (Pubitemid 351272635)
28. Connolly SJ, Ezekowitz MD, Yusuf S et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361 (12), 1139-1151 (2009).
29. *5) expressed among African Americans. Mol. Pharmacol. 60 (2), 382-387 (2001).
30. Klein TE, Altman RB, Eriksson N et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360 (8), 753-764 (2009).
31. Describes an algorithm for warfarin using pooled consortium data.